Literature DB >> 21709558

Genetics of osteoarthritis.

John Loughlin1.   

Abstract

PURPOSE OF REVIEW: A number of reasonably powered osteoarthritis genome-wide association scans are now in the final phases of their analysis, leaving us all with baited breath. This review highlights some of the osteoarthritis signals and subsequent insights that have emerged from the candidate studies and smaller scale scans that have preceded these more powered studies, and which could therefore be considered as appetizers to the hopeful treats to follow. RECENT
FINDINGS: If one applies the strict criteria of genome-wide significance thresholds, only two current signals pass muster: GDF5 and 7p22. If one relaxes slightly, other signals emerge, such as DIO2, SMAD3 and ASPN. After these, however, we enter the realm where faith takes precedence.
SUMMARY: The search for osteoarthritis susceptibility loci has not been as successful as many had anticipated. This reflects many factors, including the heterogeneous nature of the disease, the tendency to use less severe phenotypes in genetic searches and the reliance on underpowered studies. We do, however, have some successes and in the very near future others will emerge from the more powered scans. Hopefully, combining the current with the new will help our attempts to understand the cause of this complex, common arthritis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709558     DOI: 10.1097/BOR.0b013e3283493ff0

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  18 in total

1.  A SMAD3 gene polymorphism is related with osteoarthritis in a Northeast Chinese population.

Authors:  Jiang Liying; Tao Yuchun; Wang Youcheng; Wang Yingchen; Jin Chunyu; Yin Yanling; Jin Hongmei; Li Yujie
Journal:  Rheumatol Int       Date:  2013-01-06       Impact factor: 2.631

Review 2.  Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis.

Authors:  Gehua Zhen; Xu Cao
Journal:  Trends Pharmacol Sci       Date:  2014-04-15       Impact factor: 14.819

Review 3.  Hip ontogenesis: how evolution, genes, and load history shape hip morphotype and cartilotype.

Authors:  Tom Hogervorst; Wouter Eilander; Joost T Fikkers; Ingrid Meulenbelt
Journal:  Clin Orthop Relat Res       Date:  2012-12       Impact factor: 4.176

4.  Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis.

Authors:  Mary B Goldring
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-08       Impact factor: 5.346

5.  Role of SREBP2 gene polymorphism on knee osteoarthritis in the South Indian Hyderabad Population: A hospital based study with G595C variant.

Authors:  Subhadra Poornima; Krishna Subramanyam; Imran Ali Khan; Sumanlatha G; Qurratulain Hasan
Journal:  J Orthop       Date:  2019-05-07

Review 6.  The genetics and functional analysis of primary osteoarthritis susceptibility.

Authors:  Louise N Reynard; John Loughlin
Journal:  Expert Rev Mol Med       Date:  2013-02-18       Impact factor: 5.600

7.  Computed tomography of subchondral bone and osteophytes in hip osteoarthritis: the shape of things to come?

Authors:  Tom D Turmezei; Ken E S Poole
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-13       Impact factor: 5.555

8.  Allelic expression analysis of the osteoarthritis susceptibility locus that maps to MICAL3.

Authors:  Madhushika Ratnayake; Louise N Reynard; Emma V A Raine; Mauro Santibanez-Koref; John Loughlin
Journal:  BMC Med Genet       Date:  2012-03-02       Impact factor: 2.103

9.  Allelic expression analysis of the osteoarthritis susceptibility gene COL11A1 in human joint tissues.

Authors:  Emma V A Raine; Andrew W Dodd; Louise N Reynard; John Loughlin
Journal:  BMC Musculoskelet Disord       Date:  2013-03-08       Impact factor: 2.362

10.  Functional characterisation of the osteoarthritis susceptibility locus at chromosome 6q14.1 marked by the polymorphism rs9350591.

Authors:  Katherine Johnson; Louise N Reynard; John Loughlin
Journal:  BMC Med Genet       Date:  2015-09-07       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.